Home MarketMerck Ltd.

Merck Ltd. Stock Info: As on 2018-05-24 15:59:40



52 Week Range
Day's Range1,560.84 - 2,341.26
Value Traded (in ₹ Cr.) 10.07



Change %
52 Week Range
Day's Range1,570.12 - 2,355.18
Value Traded (in ₹ Cr.) 5.29

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 8,599,224.00 51.80%
IndianPromoters 0.00 0.00%
Mutual Funds/UTI 328,282.00 1.98%
FII 607,814.00 3.66%
Employee 0.00 0.00%
Public 4,768,231.00 28.73%
Government 0.00 0.00%
Others 1,032,511.00 6.22%

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 1.94
Basic EPS (Rs.) 56.60
Cash EPS 82.86
BVPerShare Excl 441.72
Operating Revenue 665.04
PBDITPerShare 107.72
Dividend 15.00
NPPerShare 56.57
Current Ratio 3.31
Quick Ratio 2.61
PriceToBV 2.92
Earnings 0.04
PBDIT Margin 16.19
PBT Margin 13.78
NP Margin 8.50
Return On Assets 9.47
Retention Ratios 80.55
Parameter Dec-17 (₹ Cr.) Yoy%change
Total Income 1,127.93
Total Expenses 992.74
EBITDA 178.82
PBT 152.19
PAT 93.91
Net Income 93.91
Parameter Dec-17 (₹ Cr.) 6M % change
Total Income 628.71
Total Expenses 543.21
EBITDA 71.78
PBT 102.50
PAT 58.96
Net Income 0.00
Total Assets
Total Assets
Parameter Dec-17 (₹ Cr.) Yoy%change
Total share capital 16.60
Net worth 733.26
Investments 69.97
Total Liability 991.22
Total debt 0.00
Net block 123.97
Total Assets 991.22
Parameter Dec-17 (₹ Cr.) 6M % change
Total share capital 16.60
Net worth 591.54
Investments 42.28
Total Liability 783.97
Total debt 0.00
Net block 138.73
Total Assets 783.97
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533.05 531.95 0.21

Abbott India Ltd.

6671.7 6587.45 1.28

Ajanta Pharma Ltd.

977.6 987 -0.95

Albert David Ltd.

362.35 362.75 -0.11

Alembic Ltd.

48.85 50.8 -3.84

Alembic Pharmaceuticals Ltd.

420.7 422.3 -0.38

Alkem Laboratories Ltd.

1957.55 1965.35 -0.4
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

47.5 49.05 -3.16

Aarti Drugs Ltd.

530 529.15 0.16

Aayush Food & Herbs Ltd.

47.7 48.1 -0.83

Abbott India Ltd.

6699.95 6593.7 1.61

ABL Bio-Technologies Ltd.

0.81 0.78 3.85

Addlife Pharma Ltd.

0.46 0 0

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
Parameter Dec-17(in ₹ Cr.)
Cash from operating activities 53.66
Cash from investing activities -47.63
Cash from financing activities -21.98
Net change in cash -15.95

Stock Held By Mutual Fund Schemes

Corporate Details

About Management

1967 - The Company was incorporated on 26th April, as a private limited company. It was converted into a public limited company on 29th June, 1981. Among the important items manufactured by the Company are specialities in the group of neurotropics such as encephabol and anti-psychotics such as lithocarb and vitamin formulations such as neurobion, polybion, multiboonata, etc. - E. Merck, Darmstadt, West Germany are the Company's collaborators who had been supplying sophisticated technical know-how to the Company free of charge. 1974 - 12,782 No. of shares issued without payment in prop. 1:3. 1977 - 2,500 bonus shares issued in prop. 1:3. 1979 - 50,000 Bonus shares issued in prop. 1:2. 1981 - The non-resident equity holding in the Company was reduced from 60% to 51% by the issue of new equity shares to resident equity shareholders and to the public. - Shares subdivided on 29.6.1981. Issued 5,02,500 shares to Chemitra GmbH, West Germany and 47,500 shares as Rights to resident Indian shareholders. 7,02,067 shares (including 2,067 shares not taken up by the resident Indian shareholders) offered at par for public subscription during August. 1985 - In order to raise funds for working capital requirements, the Company privately placed with Army Group Insurance Fund 1,00,000 - 15% non-convertible debentures of Rs 100 each. These debentures are redeemable at a premium of 5% on 12th August, 1992. The Company also privately placed with UTI 2,00,000 - 15% non-convertible redeemable debentures of Rs 100 each aggregating Rs 200 lakhs. These debentures were to be redeemed at a premium of 5% after the expiry of 7 years from the date of allotment. 1986 - Several essential drugs like Praziquantel, Septopal Beads and anti-cancer drugs were introduced. Soon, the Company intended to introduce anti-malarial and anti-inflammatory drugs. - 16,50,000 bonus equity shares issued in prop. 3:5. 1987 - A bulk drug unit, at Indore, manufacturing chloroquine phosphate and its derivatives was acquired by the Company. - The Company acquired a significant shareholding in Suneeta Laboratories, Indore, equipped with strong scientific base and professionals, with a view to manufacturing several active ingredients. - 15,40,000 shares issued (prem. Rs 10 per share); 14,66,667 shares as Rights in Prop. 1:3 (only 14,39,924 shares) taken up and (ii) 73,333 shares to employees (all were taken up). The 26,743 shares not taken up out of Rights quota were allotted privately. 1989 - The Company launched its diagonistics project. - A new pharmaceutical formulation division was launched to market formulations bearing BDH trade mark. - During March-April, the Company offered 5,50,000-14% secured redeemable non-convertible debentures of Rs 100 each for cash at par on rights basis as follows: - (i) To resident Indian shareholders in proportion 1 deb: 10 equity shares; - (ii) 1 deb: 2 debentures to debentureholders and - (iii) 1 debenture for every Rs 500 deposit held for fixed deposit holders. The debentures were to be redeemed at a premium of Rs 5 per debentures on the expiry of 7 years from the date of allotment of debentures. 1990 - The name of the Company was changed to BDH Pharmaceuticals, Ltd. The unit is manufacturing and marketing certain bulk drugs viz. chloroquine phosphate and chloroquin sulphate. The Company sold its Indore plant at a total consideration of Rs 200 lakhs to BDH Pharma, both from the point of view of locational disadvantages of having a plant at Indore and from the point of view of control. 1991 - 29,70,000 Bonus equity shares issued in prop. 1:2. 1992 - During March, the Company offered 5,55,428 - zero interest fully convertible debentures of Rs 120 each on Rights basis in the proportion 1 debenture: 10 equity shares held (all were taken up). Simultaneously another 27,772 debentures were issued to the employees on an equitable basis (all were taken up). Debentures under category (i) and (ii) were taken up. - The Company also issued the following zero interest fully convertible debentures of Rs 120 each to foreign promoters to maintain their holding to the extent of 40% in the Company: - (i) 2,49,500 debentures to Emedia Export Company GmbH and - (ii) 1,39,300 debentures to Chemilia, GmbH. Debentures under category (i) and (ii) were taken up. Each of the above mentioned zero interest debentures are to be converted into five equity shares of Rs 10 each at a premium of Rs 14 per share on 7th January, 1993. 1993 - The poor performance in the national and international market was attributed to sale of Indore plant manufacturing chloroquine phosphate and other items, and decrease in offtake of Guaiazulene to Japan respectively. - During May, the Company issued and allotted 30,91,224 new equity shares of Rs 10 each at a premium of Rs 14 per share to Merck AG or their Associates to increase their stake in the Company from the existing 40% to 51%. 1997 - During August, the Company had redeemed 14% NCD's, (Series 11) aggregating to Rs 55 million. During February 1998, the Company had redeemed one-third (second instalment) of the 16.5% NCD's aggregating to Rs 20 million held by UTI. - Taloja plant setting up a soft gelatin capsule plant in Goa and the parent E Merck of the US recently set up a 100 per cent subsidiary. - Almost all the non-pharma capacity of EMIL is being utilised and the company is already sourcing its higher needs through loan licence agreements with smaller manufacturers. 1998 - EMI, a 51-per-cent subsidiary of E Merck, Germany, has five divisions - pharma, reagents, bulk drugs, diagnostics and pigments. - E Merck (India) has assigned its popular vitamin-B complex syrup brand Polybion to a small scale manufacturer, facilitating its removal from the clutches of price control. 1999 - E Merck is unlikely to opt for the joint venture route for the OTC business and would build on its own distribution strength in contrast to other drug companies like Nicholas Pirmala. - E Merck India is one of the largest players in the vitamins market. - Buoyed by the international acquisition of a $50 million laboratory chemicals company by its parent, E Merck India will soon be able to introduce a range of premium laboratory chemicals that will facilitate research in biotechnology in the country. 2000 - E.Merck, a subsidiary of Merck of Germany and domestic pharma company Kopran have entered into a co-markering arrangement for cardiovascular drug atorvastatin. 2002 - E.Merck (India) Ltd has informed that Prof. Thomas Schereckenbach has been appointed as Additional Director. And Mr.K. J.Mallya has been appointed as the Company Secretary of the Company on November 19, 2001 and he will also be the Compliance Officer of the Company. 2004 -Merck signs Deed of Assignment with Biochem Pharmaceuticals 2007 -Merck Ltd has appointed Mr. K Shivkumar as an Additional Director. 2009 - Merck Ltd has informed that at the Meeting of the Board of Directors held on July 20, 2009 Mr. Ralph Antonius Zaat has been appointed as a Director in place of Dr. Hans Hermansson. 2010 - The Company at its meeting held on January 22, 2010, inter alia, has recommended a final dividend of Rs. 20/- per share. - Merck KGaA and sanofi-aventis Sign Agreement to Jointly Investigate Novel Combinations Against Cancer. - Merck KGaA Donation Program Supports Schistosomiasis Control in Africa. - FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-infected Patients with Lipodystrophy. 2011 - Merck KGaA Intends to Name Matthias Zachert to Executive Board. - Merck Appoints Frederic Wohlwend as CIO. - Merck Strengthens Research Cooperation With Israel. - Merck Received European Approval for Three Pre-filled, Ready-to-use Pen Injectors for Fertility Treatment. 2012 - Merck Donates100 Millionth Tablet to Treat Schistosomiasis. - Standard & Poor's Raises Merck's Long-Term Credit Rating to A- with Stable Outlook. - Merck Advances to Eighth Place in the 2012 Access to Medicine Index. - Jon Baumhauer Awarded the Luther Rose. - Merck Serono Announces Final Efficiency Program for Switzerland. 2013 -Merck Invests in Research Partnerships in Israel to Boost Innovation. 2014 -Merck Serono announced the formation of the global Oncology Partnership and Education Network (OPEN). 2015 -Merck Ltd has changed Corporate Office moved to a new location. The Company's address and contact details are given below.MERCK LIMITED Godrej One, 8th floor Pirojshanagar,Eastern Express Highway,Vikhroli(E), Mumbai 400079. -Merck Acquires Ormet Circuits -Merck Helps Refugees in Lebanon -Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab -Merck and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products 2016 -Merck Expands Distribution Agreement with Roche -Merck Wins R&D 100 Award for Top Invention -Merck Sets its Sights on 2018 and Outlines Future Strategic Roadmap -Merck Presents Its First Russian Literary Prize

Registered Office

Godrej One, 8th floor, Pirojsha Nagar, Eastern Express Highway, Vikhroli (E)

022-62109000,,,      022-62109999,



Registrar Details

Karvy Computershare Private Ltd.